



PLEASE SEE IMPORTANT DISCLOSURES & COPYRIGHT INFRINGEMENT IN THE APPENDIX

Transaction Overview

Facey Group Limited is inviting individuals to apply to purchase 91,914,894 ordinary shares of Seprod Limited. In March 2018, Seprod announced that it had reached an agreement with Facey to acquire its consumer business, Facey Commodity Holdings Limited (Facey Consumer), which deals in the distribution of consumer and pharmaceutical products in Jamaica. Seprod paid US\$53.8M to acquire Facey Consumer – US\$16M in cash and 217,148,396 newly issued shares of Seprod worth US\$37.8M.

The deal was closed in September in 2018, subject to the issuance of the shares. Facey intends to retain 125,234,043 shares for itself and is making the remaining 91.9M shares available to prospective investors as keeping them would bring Musson's (Parent company of Facey) overall stake in Seprod above 50%, triggering a mandatory takeover offer to the other shareholders.

Term Sheet

Instrument	Ordinary Shares				
Company	Seprod Limited				
Nominator	Facey Group Limited				
Lead Broker	NCB Capital Markets				
Amount	 91,914,894 shares of which 55,000,000 shares represented reserved shares: 30,000,000 shares reserved for staff, managers, executives, directors and former directors of Seprod and its subsidiaries including Facey Consumer 15,000,000 shares reserved for existing Seprod shareholders as at Aug. 31, 2018. Up to 10,000,000 				
Invitation Price	\$23.99				
Minimum Subscription	1,000 shares with increments in multiples of 100				
Use of Proceeds	None of the net proceeds of this Offer will be payable to Seprod as all the share are being made available by the Nominator.				
Important Dates	Opening Date – 9:00am October 23, 2018 Closing Date - 4:30pm on October 30, 2018				

All information contained herein is obtained by JMMB® Investment Research from sources believed by it to be accurate and reliable. All opinions and estimates constitute the Analyst's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR COMPLETENESS OF THIS REPORT IS GIVEN OR MADE BY JMMB® IN ANY FORM WHATSOEVER.



Company Background

Seprod Limited was incorporated in Jamaica in July 1940 and became a publicly-listed company in 1985. Seprod now operates with three business lines: Ingredients, Dairy and Distribution. The Ingredients division consists of Seprod's joint venture with Seaboard Corporation, Jamaica Grain and Cereals Limited, which commenced flour production in December 2017. The operation also produces cornmeal and grits in bulk as well as consumer-size packages. The sugar operation has racked up significant losses over the past few years which the company is seeking to reverse having admitted their inability to overcome the industry's "significant structural deficiencies."

The Dairy line has been expanded with integration of dairy operation formerly owned and operated by the Nestle Group, which includes the physical assets based in Bog Walk, St. Catherine and the "Betty" and "Supligen" brands. The acquisition of Facey Consumer forms the foundation of the Distribution arm of Seprod as the company saw little benefit in having first-class production facilities without the ability to distribute the products themselves.

Target Background

Facey Consumer is a leading distributor of consumer and pharmaceutical products in Jamaica and Trinidad. Facey distributes to over 8,000 locations island-wide, inclusive of supermarket chains and convenience stores. Brands distributed by Facey Consumer include:

Merchandise					
Oscar Mayer	Post	Goya	Mondelez		
Lider	Delite	Kraft	Eve		
Serge	Butterkist	Maxwell House	Twinings		
Nabisco	Brunswick	Abbot			
Pharmaceutical					
Church & Dwight	Roche	Pfizer	Limacol		
Boehringer Ingelheim					

All information contained herein is obtained by JMMB® Investment Research from sources believed by it to be accurate and reliable. All opinions and estimates constitute the Analyst's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR COMPLETENESS OF THIS REPORT IS GIVEN OR MADE BY JMMB® IN ANY FORM WHATSOEVER.



The Merchandise division is one of the largest distributors in the region and has the largest route-to-market fleet within Jamaica. The company employs real-time monitoring and reporting through the use of tablets and other smart devices by the sales and distribution teams. The Pharmaceutical division is one of the leading distributors of pharmaceutical goods in the English-speaking Caribbean with a dominant presence in Jamaica. Facey distributes a wide range of ethical and over-the-counter pharmaceuticals across its island-wide network to hospitals, pharmacies and general merchandise and convenience stores from a state-of-the-art, air-conditioned warehouse with 40,000 sq. ft. of capacity.

The following is an extract from the Prospectus for the Seprod shares which details financial information on Facey Consumer.

Facey Commodity Company Limited

Consumer EBITDA 2015-2018 (US'000s)

	YTD June 2018	2017	2016	2015	2017/2016 % change
Revenue	67,600	129,082	113,197	103,590	14.0%
Gross Profit	12,196	23,602	20,710	16,693	14.0%
Selling, General & Administrative Expense	7,178	14,439	13,743	11,226	5.1%
EBITDA	5,018	9,163	6,966	5,467	31.5%

At the time of its acquisition, Facey Consumer carried net debt of US\$20.0M with a weighted average interest rate of approximately 7.29%.

Outlook and Valuation

The information presented in the previous table is all the financial information for Facey Consumer that has been made public with this offer. Facey Consumer reported revenues of US\$129.1M for 2017 (J\$16.6B), up 14.0% from the prior year's result and compares to revenues of J\$16.5B for Seprod Limited over the same period¹. We anticipate a significant increase in revenues for Seprod

¹ See Abridged Financials Section for financial summary of Seprod Limited

All information contained herein is obtained by JMMB® Investment Research from sources believed by it to be accurate and reliable. All opinions and estimates constitute the Analyst's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR COMPLETENESS OF THIS REPORT IS GIVEN OR MADE BY JMMB® IN ANY FORM WHATSOEVER.





Limited post-transaction, however, as Facey Consumer was a distributor of Seprod products, we do not believe this acquisition will result in a doubling of Seprod's revenues.

EBITDA for Facey Consumer for 2017 amounted to US\$9.2M, or J\$1.2B, a 31.5% increase year-over-year, which compares to Seprod's EBITDA of \$1.33B for the same year. Without knowing the specific amount of net profit that was generated by Facey Consumer in past years, it is difficult to project Seprod's net earnings post-transaction and without this information we are unable to properly assess whether or not this acquisition is accretive or dilutive as the number of shares outstanding has increased by 42%.

Given the information available to us, we employed an Enterprise Value to EBITDA (EV/EBITDA) multiple to determine the fair value of Seprod. The cumulative value of Seprod's trailing twelve month EBITDA and Facey's 2017 EBITBA is \$3.0B. Applying Seprod's 1-year average EV/EBITDA multiple of 9.78x yields an enterprise value of J\$29.4B. Adjusting for net debt, the equity value of Seprod is \$29.16 (shares outstanding – 733,546,855).

Recommendation

We view favourably the moves by Seprod over the past year to expand its business operations following the acquisition of Nestle Jamaica, Facey Consumer and the joint venture with Seaboard Corporation. Investors should be mindful of the Company's investment in sugar, which has generated significant losses to date. Also, as a manufacturing, and now distribution company, Seprod is susceptible to economic headwinds stemming from weak economic growth, high inflation and weak business & consumer confidence. Deterioration in these factors would have a negative impact on the company's outlook.

We recommend this offer as OVERWEIGHT as our valuation of \$29.16 is 21.2% above the offer price of \$23.99. Assuming the dividend yield of 3.2% for 2017 is matched in 2018, the potential total return is 24.4%.

Source: http://www.Jamstockex.com, JMMB Investment & Research, Bloomberg, Company Financials, Offer Prospectus

INVESTMENT AND SOVEREIGN RESEARCH October-25-2018



Facey Group's Offer of Seprod Limited Shares

Abridged Financials

J\$ Year Ended December 31								
	2013	2014	2015	2016	2017	6M17	6M18	Change %
Turnover	13,921,759	14,007,117	13,777,863	15,781,917	16,511,206	8,365,210	10,435,383	24.7%
Cost of Sales	11,378,773	11,216,211	11,114,536	12,291,448	12,687,358	6,313,235	6,996,094	10.8%
Gross Profit	2,542,986	2,790,906	2,663,327	3,490,469	3,823,848	2,051,975	3,439,289	67.6%
Operating Eugenees	4 004 000	1 045 600	2 200 242	2 760 970	2 077 274	4 500 000	2 512 720	58.2%
Operating Expenses	1,821,868	1,815,628	2,309,243	2,760,879	2,977,371	1,589,228	2,513,720	
Operating Profit	1,419,318	1,460,478	900,823	1,588,716	1,330,969	847,295	1,154,711	36.3%
Profit Before Taxation	1,118,394	1,170,645	604,058	1,185,924	938,960	635,847	859,984	35.3%
Profit for the year	905,753	1,011,810	865,953	1,092,043	735,043	530,995	662,516	24.8%
	·							
Total Assets	13,791,649	14,035,906	15,296,202	17,216,750	20,008,056	18,078,359	20,610,691	14.0%
Total Liabilities	4,594,882	4,244,593	5,562,042	8,241,008	10,998,244	8,638,486	10,993,699	27.3%
Shareholder's Equity	9,366,647	10,077,628	10,309,528	9,767,944	9,889,214	10,301,050	10,560,512	2.5%
EPS (\$)	1.23	1.38	1.18	1.49	1.00	0.72	0.90	
Book Value per Share (\$)	12.77	13.74	14.05	13.32	13.48	14.04	14.40	
Key Ratios								
Gross profit margin	18.3%	19.9%	19.3%	22.1%	23.2%	24.5%	33.0%	
Operating profit margin	10.2%	10.4%	6.5%	10.1%	8.1%	10.1%	11.1%	
Pre-tax Margin	8.0%	8.4%	4.4%	7.5%	5.7%	7.6%	8.2%	
Net Margin	6.5%	7.2%	6.3%	6.9%	4.5%	6.3%	6.3%	
Return on Average Equity			0.0.1				0.07.	
Return on Average Assets								
Cash Ratio (x)	0.36	0.58	0.64	0.12	0.09	0.11	0.14	
Current Ratio (x)	2.09	2.62	1.83	1.11	1.30	1.13	1.67	
Debt/Equity (x)	0.24	0.23	0.29	0.35	0.38	0.32	0.60	
Net debt/EBITDA (x)	1.02	0.91	1.89	1.74	2.17			

INVESTMENT AND SOVEREIGN RESEARCH October-25-2018



Facey Group's Offer of Seprod Limited Shares

APPENDIX

IMPORTANT DISCLOSURES

ABSTRACT—As a part of our new Portfolio Strategy we are recommending strict adherence to the following Portfolio Allocation **DEFINITIONS/RECOMMENDATIONS**.

PLEASE NOTE THAT NO INDIVIDUAL ASSET IN YOUR PORTFOLIO SHOULD HAVE A WEIGHTING GREATER THAN 5% UNLESS OTHERWISE RECOMMENDED BY YOUR PORTFOLIO MANAGER OR A SPECIFIC JMMB RESEARCH REPORT. CONSEQUENTLY THE FOLLOWING <u>DEFINITIONS</u> ARE PROVIDED FOR CLARITY.

UNDERWEIGHT—REDUCE EXPOSURE IN YOUR PORTFOLIO TO LESS THAN 5% FOR THIS PARTICULAR ASSET

SELL—REDUCE EXPOSURE IN YOUR PORTFOLIO TO ZERO.

HOLD/MARKETWEIGHT—EXPOSURE TO THE ASSET SHOULD BE EQUAL TO 5% OF YOUR TOTAL PORTFOLIO HELD AT JMMB.

OVERWEIGHT/BUY—EXPOSURE TO THIS ASSET SHOULD BE BETWEEN 5% AND 10% OF YOUR TOTAL PORTFOLIO HELD AT JMMB

COPYRIGHT INFRINGEMENT

"Unless otherwise expressly stated, copyright or similar rights in all material in this research report (including graphical images) is owned, controlled or licensed by Jamaica Money Market Brokers Limited or its affiliates (JMMB) and is protected or covered by copyright, trade mark, intellectual property law and other proprietary rights. No part of this research report or the report in its entirety may be published, used, reproduced, distributed, displayed or copied for public or private use in any form including by any mechanical, photographic or electronic process (electronically, digitally on the Internet or World Wide Web, or over any network, or local area network or otherwise) without written permission from JMMB.

All information contained herein is obtained by JMMB® Investment Research from sources believed by it to be accurate and reliable. All opinions and estimates constitute the Analyst's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR COMPLETENESS OF THIS REPORT IS GIVEN OR MADE BY JMMB® IN ANY FORM WHATSOEVER.





No part of this research report may be modified or changed or exploited or used in any way for derivative works, or offered for sale, or used to construct any kind of database or mirrored at any other location without the express written permission of JMMB.

Thank you for respecting our intellectual property rights."

The investments referred to in this report may not be suitable for you should consult your licensed investment advisor. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable to your individual circumstances or otherwise constitutes a personal recommendation to you.

Disclosure Under The Securities Act

This disclosure is being provided pursuant to section 39 of the Securities Act. This research report is prepared by Jamaica Money Market Brokers Limited (JMMB) and the information and views expressed are those of JMMB. JMMB is a subsidiary of the JMMB Group Limited (JMMBGL). Associated persons of JMMB include JMMBGL and its subsidiaries and affiliated companies, including JMMB Fund Managers Limited, a licensed securities dealer and manager of collective investment schemes.

As at the date of this report, JMMB and its affiliates, directors, officers, employees and other associated persons may from time to time buy or sell, or act as principal or agent in, the securities mentioned in this research report. JMMB or its affiliates, directors, officers and employees have no interest in or interest in the acquisition or disposal of the securities other than expressed above. No part of their compensation is or will be related to the recommendations or opinions in this report.